Roche Holding (RHHBY)
(Delayed Data from OTC)
$30.31 USD
+0.06 (0.20%)
Updated Apr 29, 2024 03:48 PM ET
4-Sell of 5 4
C Value C Growth D Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RHHBY 30.31 +0.06(0.20%)
Will RHHBY be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for RHHBY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RHHBY
AbbVie (ABBV) Beats on Q1 Earnings & Sales, Ups '24 EPS View
Roche (RHHBY) Q1 Hit by Currency Headwinds, Lower COVID-19 Sales
RHHBY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Novartis (NVS) Q1 Earnings, Sales Beat, Guidance Raised
Roche (RHHBY) Alecensa Wins FDA Nod for Label Expansion
Pharma Stock Roundup: JNJ's Q1 Results, LLY, ABBV, RHHBY's Successful Study Data
Other News for RHHBY
J&J, Roche, AstraZeneca poised to have highest orphan drug sales by end of decade
Roche: Value Remains Despite Covid-19 Revenue Growth Loss
AbbVie's Q1: Positive Surprise
Roche price target lowered by CHF 10 at UBS
Roche price target lowered by CHF 20 at Barclays